Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. more
Time Frame | NBSE | Sector | S&P500 |
---|
Sep '18 | Sep '19 | Sep '20 | Sep '21 | Sep '22 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2018-09-30","value":"-","profit":true},{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true}] |
Cost of Revenue | 13.90M | 128.37K | 280.46K | 575.52K | 1.26M | [{"date":"2018-09-30","value":100,"profit":true},{"date":"2019-09-30","value":0.92,"profit":true},{"date":"2020-09-30","value":2.02,"profit":true},{"date":"2021-09-30","value":4.14,"profit":true},{"date":"2022-09-30","value":9.08,"profit":true}] |
Gross Profit | (13.90M) | (128.37K) | (280.46K) | (575.52K) | (1.26M) | [{"date":"2018-09-30","value":-1390395500,"profit":false},{"date":"2019-09-30","value":-12837200,"profit":false},{"date":"2020-09-30","value":-28046300,"profit":false},{"date":"2021-09-30","value":-57552100,"profit":false},{"date":"2022-09-30","value":-126251200,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2018-09-30","value":null,"profit":false},{"date":"2019-09-30","value":null,"profit":false},{"date":"2020-09-30","value":null,"profit":false},{"date":"2021-09-30","value":null,"profit":false},{"date":"2022-09-30","value":null,"profit":false}] |
Operating Expenses | 9.08M | 26.34M | 17.07M | 26.57M | 33.32M | [{"date":"2018-09-30","value":27.25,"profit":true},{"date":"2019-09-30","value":79.04,"profit":true},{"date":"2020-09-30","value":51.23,"profit":true},{"date":"2021-09-30","value":79.73,"profit":true},{"date":"2022-09-30","value":100,"profit":true}] |
Operating Income | (13.90M) | (26.34M) | (17.07M) | (26.57M) | (33.32M) | [{"date":"2018-09-30","value":-1390395500,"profit":false},{"date":"2019-09-30","value":-2633640700,"profit":false},{"date":"2020-09-30","value":-1706930600,"profit":false},{"date":"2021-09-30","value":-2656544700,"profit":false},{"date":"2022-09-30","value":-3331833900,"profit":false}] |
Total Non-Operating Income/Expense | (4.16M) | (750.79K) | (322.90K) | 1.14M | (333.60K) | [{"date":"2018-09-30","value":-365.96,"profit":false},{"date":"2019-09-30","value":-66.07,"profit":false},{"date":"2020-09-30","value":-28.42,"profit":false},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-29.36,"profit":false}] |
Pre-Tax Income | (13.24M) | (26.96M) | (17.38M) | (25.41M) | (33.78M) | [{"date":"2018-09-30","value":-1323690000,"profit":false},{"date":"2019-09-30","value":-2695824700,"profit":false},{"date":"2020-09-30","value":-1738452000,"profit":false},{"date":"2021-09-30","value":-2540930100,"profit":false},{"date":"2022-09-30","value":-3377645000,"profit":false}] |
Income Taxes | 8.98M | 128.95K | (123.27K) | 258.11K | 458.11K | [{"date":"2018-09-30","value":100,"profit":true},{"date":"2019-09-30","value":1.44,"profit":true},{"date":"2020-09-30","value":-1.37,"profit":false},{"date":"2021-09-30","value":2.87,"profit":true},{"date":"2022-09-30","value":5.1,"profit":true}] |
Income After Taxes | (22.22M) | (27.09M) | (17.26M) | (25.67M) | (34.23M) | [{"date":"2018-09-30","value":-2222133900,"profit":false},{"date":"2019-09-30","value":-2708719800,"profit":false},{"date":"2020-09-30","value":-1726125300,"profit":false},{"date":"2021-09-30","value":-2566740600,"profit":false},{"date":"2022-09-30","value":-3423456100,"profit":false}] |
Income From Continuous Operations | (13.24M) | (26.34M) | (17.38M) | (25.41M) | (33.78M) | [{"date":"2018-09-30","value":-1323690000,"profit":false},{"date":"2019-09-30","value":-2633640700,"profit":false},{"date":"2020-09-30","value":-1738452000,"profit":false},{"date":"2021-09-30","value":-2540930100,"profit":false},{"date":"2022-09-30","value":-3377645000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2018-09-30","value":"-","profit":true},{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true}] |
Net Income | (13.24M) | (27.09M) | (17.26M) | (25.67M) | (34.23M) | [{"date":"2018-09-30","value":-1323690000,"profit":false},{"date":"2019-09-30","value":-2708719800,"profit":false},{"date":"2020-09-30","value":-1726125300,"profit":false},{"date":"2021-09-30","value":-2566740600,"profit":false},{"date":"2022-09-30","value":-3423456100,"profit":false}] |
EPS (Diluted) | (2.52) | (3.26) | (0.89) | (0.92) | (1.04) | [{"date":"2018-09-30","value":-252,"profit":false},{"date":"2019-09-30","value":-326,"profit":false},{"date":"2020-09-30","value":-89,"profit":false},{"date":"2021-09-30","value":-92,"profit":false},{"date":"2022-09-30","value":-104,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NBSE | |
---|---|
Cash Ratio | 2.70 |
Current Ratio | 2.87 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NBSE | |
---|---|
ROA (LTM) | -43.03% |
ROE (LTM) | -93.46% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NBSE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.51 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.49 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NBSE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.18 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.19 |
NeuBase Therapeutics Inc (NBSE) share price today is $
Yes, Indians can buy shares of NeuBase Therapeutics Inc (NBSE) on Vested. To buy NeuBase Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NBSE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of NeuBase Therapeutics Inc (NBSE) via the Vested app. You can start investing in NeuBase Therapeutics Inc (NBSE) with a minimum investment of $1.
You can invest in shares of NeuBase Therapeutics Inc (NBSE) via Vested in three simple steps:
The 52-week high price of NeuBase Therapeutics Inc (NBSE) is $1.15. The 52-week low price of NeuBase Therapeutics Inc (NBSE) is $0.36.
The price-to-earnings (P/E) ratio of NeuBase Therapeutics Inc (NBSE) is
The price-to-book (P/B) ratio of NeuBase Therapeutics Inc (NBSE) is 0.18
The dividend yield of NeuBase Therapeutics Inc (NBSE) is 0.00%
The market capitalization of NeuBase Therapeutics Inc (NBSE) is $1.42M
The stock symbol (or ticker) of NeuBase Therapeutics Inc is NBSE